Positive efficacy and safety data in Chinese patients could unlock regional expansion for the HA filler.
Galderma announced positive topline results for Restylane Volyme in correcting moderate-to-severe temple hollowing in Chinese patients. The study demonstrated high effectiveness and satisfaction alongside a robust safety profile—a critical data point for regional regulatory approval and market penetration in Asia-Pacific.
Temple volume loss is a distinct aesthetic concern in East Asian populations, and Volyme's crosslinked hyaluronic acid formulation is engineered for substantive lift and longevity. The filler's rheology supports three-dimensional correction in a delicate zone where precision and natural contour matter. This trial outcome positions Galderma to pursue local registration and compete directly against Allergan Aesthetics' regional installed base.
Positive efficacy and safety data unlock regional expansion for Restylane Volyme in Asia-Pacific.
For practices with Asian patient demographics, the data validates Volyme's off-label utility in temple augmentation—a procedure gaining traction as patients seek subtle facial architecture refinement without surgical intervention.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
